Back to BAKER BROS. ADVISORS LP BAKER BROS. ADVISORS LP

PRLDPRLD
Showing 8 of 24 quarters

Position history for BAKER BROS. ADVISORS LPBAKER BROS. ADVISORS LP's holdings in PRELUDE THERAPEUTICS INC

BAKER BROS. ADVISORS LP holds 10.1M shares of PRLD (PRELUDE THERAPEUTICS INC), worth $54M as of 2026-Q2. PRLD represents 0.3% of BAKER BROS. ADVISORS LP's portfolio.

Current Value

$54M

Current Shares

10.1M

Total Value Change

+$33M

Total Shares Change

0

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Unchanged
10.1M
0.0%
$54M0.3%$5.33
0
2026-Q1
Unchanged
10.1M
0.0%
$34.6M0.2%$2.63
0
2025-Q4
Unchanged
10.1M
0.0%
$29.4M0.2%$2.84
0
2025-Q3
Unchanged
10.1M
0.0%
$14.6M0.1%$1.37
0
2025-Q2
Unchanged
10.1M
0.0%
$8.2M0.1%$0.79
0
2025-Q1
Unchanged
10.1M
0.0%
$7.8M0.1%$0.80
0
2024-Q4
Unchanged
10.1M
0.0%
$12.9M0.1%$1.21
0
2024-Q3
Unchanged
10.1M
0.0%
$21M0.2%$2.12
0

Other major holders of PRLD: HHLR ADVISORS, LTD., UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC, RA CAPITAL MANAGEMENT, L.P.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used